These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review. Mohyuddin GR; Koehn K; Abdallah AO; W Sborov D; Rajkumar SV; Kumar S; McClune B Am J Hematol; 2021 Jun; 96(6):690-697. PubMed ID: 33735453 [TBL] [Abstract][Full Text] [Related]
5. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018. Schuster Bruce C; Brhlikova P; Heath J; McGettigan P PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034 [TBL] [Abstract][Full Text] [Related]
6. Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials. Beck EJ; Sherry AD; Florez MA; Kouzy R; Abi Jaoude J; Lin TA; Miller AM; Passy AH; Kupferman GS; Patel RR; Chino F; Higbie VS; Parseghian CM; Overman MJ; Minsky BD; Thomas CR; Tang C; Msaouel P; Ludmir EB Cancer Res Commun; 2024 Aug; 4(8):2183-2188. PubMed ID: 39099199 [TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
8. Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors. Di Costanzo F; Napolitano F; Salomone F; Amato AR; Alberico G; Migliaccio F; Pecoraro G; Marra A; Crocetto F; Ruffo A; Scagliarini S; Rossetti S; Puglia L; Di Napoli M; Bianco R; Servetto A; Formisano L Cancers (Basel); 2023 Dec; 15(23):. PubMed ID: 38067406 [TBL] [Abstract][Full Text] [Related]
9. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval. Loncharich MF; Anderson CW ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371 [TBL] [Abstract][Full Text] [Related]
10. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND; Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525 [TBL] [Abstract][Full Text] [Related]
11. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
12. Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials. Zhang Z; Pan Q; Lu M; Zhao B EClinicalMedicine; 2023 Sep; 63():102156. PubMed ID: 37600482 [TBL] [Abstract][Full Text] [Related]
13. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists. Methy N; Bedenne L; Bonnetain F BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166 [TBL] [Abstract][Full Text] [Related]
14. Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials. Patel RB; Vaduganathan M; Samman-Tahhan A; Kalogeropoulos AP; Georgiopoulou VV; Fonarow GC; Gheorghiade M; Butler J Am J Cardiol; 2016 Jun; 117(11):1845-50. PubMed ID: 27085935 [TBL] [Abstract][Full Text] [Related]
15. Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation Over the Last 15 Years: A Systematic Review. Shahzad M; Khalid MF; Amin MK; Ammad-Ud-Din M; Ilyas U; Mushtaq AH; Butt A; Anwar I; Chaudhary SG; Ahmed N; Shune L; Singh AK; Abhyankar SH; McGuirk JP; Mushtaq MU Hematol Oncol Stem Cell Ther; 2024 Mar; 17(2):88-94. PubMed ID: 38560970 [TBL] [Abstract][Full Text] [Related]
16. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings. Hua T; Gao Y; Zhang R; Wei Y; Chen F BMC Cancer; 2022 Sep; 22(1):1022. PubMed ID: 36171546 [TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140 [TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R; Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625 [TBL] [Abstract][Full Text] [Related]
19. Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 Patients. Woo S; Suh CH; Wibmer AG; Becker AS; Teo MY; Gönen M; Hricak H; Scher HI; Morris MJ; Vargas HA Clin Genitourin Cancer; 2022 Feb; 20(1):69-79. PubMed ID: 34903480 [TBL] [Abstract][Full Text] [Related]